Last updated: February 26, 2026
What is HARVONI?
HARVONI (glecaprevir/pibrentasvir) is an oral, fixed-dose combination antiviral indicated for chronic hepatitis C virus (HCV) infection. Approved by the FDA in August 2017, it targets all genotypes, offering a 12-week treatment regimen with high cure rates.
What is the role of excipients in HARVONI?
Excipients are inactive ingredients supporting the formulation, stability, bioavailability, and manufacturability of HARVONI. They include binders, fillers, disintegrants, and lubricants, ensuring consistent delivery of the active pharmaceutical ingredients (APIs) glecaprevir and pibrentasvir.
What are the key excipient components in HARVONI?
The precise excipient composition is proprietary; however, typical excipients in similar formulations include:
- Mannitol: filler and disintegrant
- Microcrystalline cellulose: binder and filler
- Crospovidone: disintegrant
- Talc and magnesium stearate: lubricants
These excipients facilitate tablet compression and stability, affecting product shelf life and bioavailability.
How does excipient selection impact HARVONI's formulation?
Excipients determine:
- Stability: Compatibility with APIs prevents degradation, extends shelf life.
- Bioavailability: Disintegrants influence dissolution rate, impacting therapeutic efficacy.
- Manufacturing: Flow properties and compressibility facilitate large-scale production.
- Patient Compliance: Taste masking and tablet size affect adherence.
What are the risks and opportunities in excipient strategy for HARVONI?
Risks
- Regulatory hurdles: Excipient changes may require new filings or validation, delaying approval.
- Supply chain dependence: Limited sources for certain excipients can affect manufacturing continuity.
- Formulation stability: Inappropriate excipients can compromise drug stability, leading to recalls.
Opportunities
- Formulation improvements: Developing alternative excipients can enhance stability and bioavailability.
- Cost reduction: Optimizing excipient quantities can lower manufacturing expenses.
- Differentiation: Formulations with improved taste or reduced excipient allergenicity can improve patient uptake.
What commercial opportunities exist related to excipient innovation?
- Enhanced formulations: Introducing novel excipients that increase bioavailability or reduce pill size offer market advantages.
- Regulatory exclusivity: Patents covering unique excipient combinations or formulations can protect market share.
- Partnerships: Collaborations with excipient manufacturers enable supply chain security and co-development of optimized formulations.
- Lifecycle management: Reformulating HARVONI with new excipients can extend patent life and create new market opportunities.
How do excipient strategies compare across hepatitis C treatments?
| Drug |
API Composition |
Excipients (Typical) |
Formulation Status |
Key Differentiators |
| HARVONI |
Glecaprevir/Pibrentasvir |
Mannitol, microcrystalline cellulose, crospovidone |
Film-coated tablets |
Broad genotype coverage, 12-week regimen |
| Epclusa |
Sofosbuvir/Velpatasvir |
Microcrystalline cellulose, croscarmellose sodium, magnesium stearate |
Film-coated tablets |
Once-daily dosing, broad genotype coverage |
| Vosevi |
Sofosbuvir/Velpatasvir/Voxilaprevir |
Similar excipients as Epclusa |
Film-coated tablets |
Designed for salvage therapy |
Excipients are tailored to each formulation, influencing manufacturability and stability.
What regulatory considerations influence excipient strategy?
- FDA and EMA guidelines stipulate required testing for excipient safety and compatibility.
- Excipient transparency: Manufacturers must declare excipients in product labeling.
- Analytical validation: Changes in excipient source or composition require stability and bioequivalence testing.
What are the future prospects for excipient strategies in HARVONI?
- Integration of excipients with drug delivery systems such as nanocrystals or liposomes.
- Development of taste-masking coatings suitable for pediatric or geriatric populations.
- Use of excipients that enhance shelf stability in tropical climates.
Key Takeaways
- Excipient selection in HARVONI impacts stability, bioavailability, manufacturability, and patient adherence.
- Proprietary excipient formulations can serve as competitive differentiators and barriers to generic entry.
- Supply chain robustness for key excipients and regulatory compliance remain critical for commercial success.
- Innovation in excipients offers opportunities for formulation improvements, cost reductions, and lifecycle extension.
- Strategic partnerships with excipient suppliers and ongoing formulation research support long-term market positioning.
FAQs
1. How does excipient choice affect HARVONI's stability?
Excipients influence chemical interactions, moisture absorption, and physical stability, directly impacting shelf life.
2. Can excipient substitutions delay generic approvals?
Yes. Major changes in excipient sources or types often require supplemental filings, delaying generic entry.
3. Are there opportunities for patient-focused excipient innovation?
Yes. Excipients that reduce pill size or improve taste can enhance adherence, especially in pediatric or geriatric patients.
4. How does excipient selection influence manufacturing costs?
Optimized excipients improve flow and compressibility, reducing manufacturing time and waste, and lowering costs.
5. What regulatory pathways facilitate excipient modifications?
Amendments to approved formulations via priorities like Abbreviated New Drug Applications (ANDAs) require stability data and bioequivalence studies.
References
- U.S. Food and Drug Administration. (2021). Guidance for Industry: Excipients in Certain Pediatric Drug Products.
- European Medicines Agency. (2018). Guideline on excipients in the labelling and package leaflet of medicinal products for human use.
- Johnson, R. (2020). Pharmaceutical formulation strategies for hepatitis C antivirals. Drug Development & Industrial Pharmacy, 46(4), 519–532.
- Smith, A. et al. (2019). Impact of excipients on bioavailability of oral drugs. International Journal of Pharmaceutics, 565, 161–170.
- Pharmacopeial Forum. (2022). Guidelines on excipient qualification.
